GlassScriptPhysician profile
Sujatha Reddy
NPI 1962498600
$116,121.84
in general payments reported to CMS, 2019-2025
44 companies · $34K in 2025
The $34K reported for 2025 was more than what 99% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $869 · 2021: $1,237 · 2022: $9,532 · 2023: $29K · 2024: $18K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $66K · Travel and Lodging: $9,386 · Food and Beverage: $5,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,922.50 |
| Travel and Lodging | $9,385.89 |
| Food and Beverage | $5,195.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $83,910.81 | 2019-2025 | Veozah, Myrbetriq |
| Lupin INC. | $22,982.88 | 2019-2021 | |
| Evofem Biosciences, INC. | $3,059.77 | 2021-2025 | Phexxi, Solosec, Phexx |
| Abbvie INC. | $964.13 | 2019-2023 | |
| Pfizer INC. | $574.27 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $387.25 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $341.58 | 2019-2025 | |
| Astellas Pharma Global Development | $297.25 | 2023-2025 | Veozah |
| Therapeuticsmd, INC. | $295.42 | 2019-2022 | |
| Amgen INC. | $295.24 | 2019-2025 | Evenity, Prolia |
| Millicent US INC | $285.19 | 2020-2025 | Intrarosa, Femlyv |
| Novo Nordisk INC | $275.28 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Sumitomo Pharma America, INC. | $243.97 | 2023-2025 | Myfembree, Gemtesa |
| Exeltis, USA INC. | $237.19 | 2019-2025 | Slynd |
| Aspira Women'S Health INC | $191.50 | 2021 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sujatha Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.